Pharmaceuticals Pipeline Overview[1]

(as of October 26, 2026)

Oncology | Cardiovascular & Renal | Neurology & Rare Diseases | Immunology | Others

Phase I

VVD KEAP1 Activator *(VVD-130037 aka NRF2 Inh, BAY 3605349)*	NME
Actinium (225Ac) Felivotide Mopaxetan *(BAY 3563254)*	NME
SOS1 Inhibitor *(BAY 3498264)*	NME
PRMT5 Inhibitor *(BAY 3713372)*	NME
VVD RAS-PI3K Inhibitor *(VVD-159642, BAY 3674171)*	NME
225Ac-GPC3 *(BAY 3547926)*	NME
KRAS G12D Inhibitor *(BAY 3771249)*	NME
Dual FIIa/Xa Inhibitor *(BAY 3389934)*	NME
BAY 3620122	NME
Ametefgene Parvec (AAV Gene Therapy) *(AB-1005)* Multiple System Atrophy	NME
Pompe Disease AAV Gene Therapy *(AB-1009 aka PROGRESS-GT LOPD)*	NME
LGMD2I/R9 AAV Gene Therapy *(AB-1003 aka LION-101)*	NME
Lemiretprocel (Cell Therapy) *(OpCT-001)* Primary Photoreceptor Diseases	NME
AT-05 SPECT Tracer	NME

Phase II

Sevabertinib (HER2/mEGFR Inhibitor) *(BAY 2927088)* // Metastatic or Unresectable Solid Tumors With HER2-activating Mutations (panSOHO)	IE
VVD WRN Inhibitor *(VVD-133214, BAY 3772392)* // Advanced Colorectal Cancer	NME
Umiposgene Parvec (AAV Gene Therapy) *(AB-1002)* // Congestive Heart Failure (GenePHIT)	NME
Inclocibart (anti-a2AP) *(BAY 3018250)* // Acute Ischemic Stroke; Pulmonary Embolism (SIRIUS)	NME
Nurandociguat (sGC Activator Oral) *(BAY 3283142)* // Chronic Kidney Disease (ALPINE-1)	NME
SEMA 3a Inhibitor *(BAY 3401016)* // Alport Syndrome (ASSESS)	NME
GIRK4 Inhibitor *(BAY 3389934)* // Atrial Fibrillation (CARDIOVERT)	NME
Ametefgene Parvec (AAV Gene Therapy) *(AB-1005)* // Parkinson´s Disease (REGENERATE-PD)	NME
Edonentan (ER Antagonist) *(PER-001, BAY 3826827)* // Non-proliferative Diabetic Retinopathy // Glaucoma	NME

Phase III

Darolutamide (AR Inhibitor) // Adjuvant Prostate Cancer (DASL-HiCaP) // Prostate Cancer with Biochemical Recurrence after Curative Radiotherapy (ARASTEP)	IE
Bemdaneprocel (Cell Therapy) // Parkinson's Disease (exPDite-2)	NME
124I-Evuzamitide (PET Tracer) // Diagnosis of Cardiac Amyloidosis (REVEAL)	NME

Submissions

Sevabertinib (HER2/mEGFR Inhibitor) // CN: Advanced NSCLC 1L	IE
Finerenone (MR Antagonist) // CN, JP, US: Non-diabetic Chronic Kidney Disease	IE
Asundexian (FXIa Inhibitor) // EU, JP, US: 2º Stroke Prevention	NME
Aflibercept 8mg (VEGF-Inhibitor) // CN: Retinal Vein Occlusion	IE
Gadoquatrane (High Relaxivity Contrast Agent) // CN, EU: Magnetic Resonance Imaging	NME

Small Molecule | Radionuclide Therapy | Genetic Therapy | Cell Therapy | Imaging Agent | Protein Therapy

NME New Molecular Entity | IE Indication Expansion

1 Bayer and partner sponsored + 3rd party label enabling studies with first patient first visit